Endevica Bio – The Cachexia Connection in Cancer
Dr. Kenneth Gruber, Founder and Chief Scientific Officer of Endevica Bio, a company focused on a new standard of care for cancer cachexia patients, discusses cachexia, also known as wasting syndrome, why it’s so prevalent in cancer, and the challenges of treating it. He talks about the current research and what might be on the horizon.
Dr. Kenneth Gruber, is the Founder, former CEO, and current Chief Scientific Officer of Endevica Bio. He is a former National Institutes of Health Branch Chief, and spent decades in academia as an NIH-funded investigator. He is the inventor on its six patents (3 US & 3 EU) which protect the intellectual property used to develop TCMCB07, as well as other peptide therapeutics. He was the principal investigator on $4.5 million in NIH/NCI SBIR grants. These grants funded the development of the platform technology that produced Endevica’s lead drug-like melanocortin antagonist peptide (TCMCB07), and the basic drug development research.
